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Abstract
The transcription factor eomesodermin (EOMES) promotes interleukin (IL)-10 expression in CD4+ T cells, which has been
linked to immunosuppressive and cytotoxic activities. We detected cytotoxic, programmed cell death protein-1 (PD-1) and
EOMES co-expressing CD4+ T cells in lymph nodes (LNs) of patients with chronic lymphocytic leukemia (CLL) or diffuse
large B-cell lymphoma. Transcriptome and flow cytometry analyses revealed that EOMES does not only drive IL-10
expression, but rather controls a unique transcriptional signature in CD4+ T cells, that is enriched in genes typical for T
regulatory type 1 (TR1) cells. The TR1 cell identity of these CD4
+ T cells was supported by their expression of interferon
gamma and IL-10, as well as inhibitory receptors including PD-1. TR1 cells with cytotoxic capacity accumulate also in Eµ-
TCL1 mice that develop CLL-like disease. Whereas wild-type CD4+ T cells control TCL1 leukemia development after
adoptive transfer in leukopenic Rag2−/− mice, EOMES-deficient CD4+ T cells failed to do so. We further show that TR1
cell-mediated control of TCL1 leukemia requires IL-10 receptor (IL-10R) signaling, as Il10rb-deficient CD4+ T cells
showed impaired antileukemia activity. Altogether, our data demonstrate that EOMES is indispensable for the development
of IL-10-expressing, cytotoxic TR1 cells, which accumulate in LNs of CLL patients and control TCL1 leukemia in mice in
an IL-10R-dependent manner.
Introduction
Despite abundant phenotypical data characterizing CD4+
T cells in chronic lymphocytic leukemia (CLL), their role in
disease development and progression is controversial and
poorly understood [1]. Besides the well-known T helper (Th)
cell subsets [1], interleukin (IL-)10-producing, FOXP3− CD4+
T cells, named T regulatory type 1 (TR1) cells, are lately
gaining attention in chronic inflammatory diseases and cancer
[2–5]. TR1 cells are described as IL-10-induced cells that
produce IL-10 and harbor cytotoxic activity, but also express
several co-inhibitory receptors such as programmed cell death
protein-1 (PD-1) [5].
Increased expression of PD-1 in blood-derived CD4+
T cells has been reported for CLL [1, 6–8] and other B-cell
non-Hodgkin lymphomas (B-NHL), including diffuse large
B-cell lymphoma (DLBCL) [9, 10]. Yet, the role of these
PD-1+ CD4+ T cells in CLL has not been studied. Blockade
of PD-1 or its ligand PD-L1, with the aim to enhance CD8+
T cell-mediated antitumoral immunity, resulted in good
response rates in the Eµ-TCL1 mouse model of CLL
[11, 12]. However, clinical trials using immune checkpoint
inhibitors targeting the PD-1/PD-L1 axis lead to dis-
appointing results. None of the included CLL patients
achieved remission in response to therapy and only a
subgroup of patients, harboring a more aggressive
Richter’s transformation, benefitted from this treatment
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(NCT02332980) [13]. It was hypothesized that the lack of
clinical success of PD-1 blockade in CLL was due to the
fact that tumor-infiltrating T cells in CLL have a lower
expression of PD-1 in comparison to other B-NHL entities,
including DLBCL [10]. In DLBCL, PD-1 expression was
shown to correlate with better survival [14, 15]. However,
immune checkpoint blockade resulted in an overall
response rate of only about 10% in DLBCL patients
(NCT02038933) [16].
Recently, the transcription factor eomesodermin (EOMES)
has been shown to promote IL-10 production of TR1 cells
together with other factors, like PR domain zinc finger pro-
tein 1 (BLIMP1), both in mice and humans [2–4]. EOMES
belongs to the T-box transcription factor family, which is
expressed in many organs including the immune system [17].
Redundantly with its paralogue T-BET, EOMES has been
shown to promote interferon gamma (IFNγ) production and
cytotoxicity in natural killer (NK) cells [18–20], CD8+
[19–21], and CD4+ T cells [2, 3, 19, 22, 23]. EOMES has
also a nonredundant role in promoting maturation of classical
NK cells [24], and in the accumulation of central memory
[20, 25] and exhausted, PD-1-expressing CD8+ T cells [26].
Co-expression of PD-1 and EOMES in CD8+ T cells was
recently shown by us in the Eµ-TCL1 adoptive transfer
(TCL1 AT) mouse model of CLL [27].
In contrast to NK cells and CD8+ T lymphocytes, very few
CD4+ T cells express EOMES without immunological chal-
lenge. However, we and others have shown that EOMES can
be upregulated in CD4+ T cells upon their activation, which
affects their differentiation into helper cell lineages [28].
Moreover, EOMES promotes IFNγ expression by Th1 T cells
[29–31] and inhibits differentiation of Th17 [3, 31, 32] and
FOXP3+ regulatory T cells (Treg) [28].
Here, we observed the accumulation of an EOMES-
expressing PD-1+ CD4+ T-cell subset in CLL patients and
mouse models, which we identify as TR1 cells. We further
show that these cells harbor cytotoxic function and are able
to control leukemia development in mice in an EOMES-
and IL-10 receptor (IL-10R)-dependent way.
Methods
Patient samples
Patient samples were obtained after approval of study pro-
tocols by local ethics committees from the Department of
Internal Medicine III of the University Clinic Ulm, the
Department of Medicine V of the University Clinic Hei-
delberg, and the Hospital Clinic of Barcelona according to
the declaration of Helsinki, and after obtaining informed
consent of patients. Patients met standard diagnosis criteria
for CLL or DLBCL, respectively. Patient characteristics
such as age, mutational state, and Binet stage are provided
in Supplementary Tables 1–3. Healthy, age-matched con-
trols were obtained from Biomex GmbH (Heidelberg,
Germany) after informed consent.
Tumor models and adoptive CD4+ T-cell transfer
Adoptive transfer of mouse leukemic cells was performed
by i.p. or i.v. transplantation of 1–2 × 107 Eμ-TCL1 sple-
nocytes into C57BL/6N or J wild-type (WT) female animals
of 6–8 weeks of age. For CD4+ co-transfer experiments,
female Rag2−/− mice of 6–8 weeks of age were i.v. trans-
planted with 2 × 105 CD4+ T cells or PBS as control. The
following day, 1 × 106 purified TCL1 leukemic cells were
transferred i.v. into recipients.
Adoptive transfer of naive CD4+ T cells was performed
as previously described [28]. In brief, Rag2−/− recipient
mice received 4 × 105 FACS-sorted CD4+CD45RBhigh
T cells by i.p. injection. Three weeks post transfer, mice
were sacrificed, and spleens were analyzed. A list of anti-
bodies used in this study is available in Supplementary
Table 4.
All animal experiments were carried out according to
institutional and governmental guidelines approved by the
local authorities (Regierungspräsidium Karlsruhe, permit
numbers: G36/14, G98/16, G123/14, and Regierung-
spräsidium Freiburg, permit number: 35-9185.81/G-13/73).
Statistical analysis
Sample size was determined based on expected variance of
readout. No samples or animals were excluded from the
analyses. No randomization or blinding was used in animal
studies. The statistical test used for each data set is indicated
in the figure legends. Samples of different groups were
compared using nonparametric Mann–Whitney test. Com-
parison of matched samples was performed using Wilcoxon
matched-pairs signed rank test. Values of p < 0.05 were
considered statistically significant. All graphs show means
± standard error of the mean (SEM), unless otherwise
indicated.
Results
Cytotoxic EOMES+ PD-1+ TR1-like CD4
+ T cells
accumulate in lymph nodes (LNs) of CLL patients
According to published data [1, 6, 8–10, 33–35], we
observed an accumulation of PD-1-expressing CD4+ T cells
in blood samples of patients with CLL or DLBCL in com-
parison to healthy controls (HC) (Supplementary Fig. 1A–E),
and subsequently aimed to characterize these cells.
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Since PD-1 has been shown to be expressed by TR1 cells [5],
we investigated the frequency of EOMES and PD-1 co-
expressing TR1-like cells and observed no difference in the
frequency of these cells in the blood of CLL patients and
controls (Supplementary Fig. 1F). In line, no substantial
changes in the frequency of EOMES+ PD-1+ TR1-like cells
were observed in sequential blood samples of CLL patients
over 5 years (Supplementary Fig. 1G). Since TR1 cells were
shown to exert cytotoxic functions [5], we analyzed the
cytotoxic molecule granzyme B (GzmB), the degranulation
marker CD107a, and IFNγ in PD-1+ versus PD-1− CD4+
T cells. This clearly showed that PD-1+ cells have a higher
cytotoxic capacity compared to PD-1− cells in both CLL
patients and controls (Supplementary Fig. 2A–F) confirming
that PD-1-expressing CD4+ T cells have cytotoxic capacity,
also in CLL.
As we and others have recently highlighted clear dif-
ferences in the phenotype of T cells in peripheral blood
compared to LNs in CLL, with a phenotype of T-cell
activation and exhaustion only in the tissue but not in blood
[34, 36], we investigated the abundance and frequency of
EOMES+ PD-1+ TR1-like cells in secondary lymphoid
organs (SLO) of patients. Intriguingly, we detected a higher
number of CD4+ T cells per CLL cell in LNs compared to
paired blood samples (Supplementary Fig. 2G), and a sig-
nificantly higher frequency of TR1-like cells in LNs
(Fig. 1A), which moreover revealed a higher activation state
based on CD69 and HLA-DR expression (Supplementary
Fig. 2H). These results suggest that TR1-like cells are of
pathological relevance in SLO of patients with CLL.
We further analyzed the transcription factors interferon
regulatory factor 4 (IRF4) and basic leucine zipper ATF-
like transcription factor (BATF), which were shown to be
involved in the development of TR1 cells [5], in paired
blood and LN samples of CLL patients. We observed a
higher expression of IRF4 and BATF in PD-1+ CD4+
T cells in LN compared to blood (Supplementary Fig. 2I, J),
supporting the results of an increased frequency of TR1-like
cells in SLO of CLL patients. By analyzing the cytotoxic
proficiency of T cells, we observed a higher CD107a and
IFNγ expression in PD-1+ compared to PD-1− cells in the
LN (Fig. 1B), which is in line with our observation in blood
and our hypothesis of a pathological relevance of TR1-
like cells.
Ultimately, we aimed to compare the frequency of TR1-
like cells in reactive, nonmalignant LNs (rLNs) versus CLL
and DLBCL LNs. We detected a substantial proportion of
TR1-like cells in all investigated CLL (median: 12.90%) and
DLBCL (median: 14.75%) LN samples. In contrast, the
majority of rLNs had a lower frequency (median: 4.85%) of
this cell type (Fig. 1C and Supplementary Fig. 2K).
Hence, TR1-like CD4
+ T cells show cytotoxic abilities
and accumulate in LNs of CLL and DLBCL patients,
making their potential pathological involvement in these
malignancies very likely.
EOMES controls a TR1 cell-specific gene signature
including inhibitory receptors in CD4+ T cells
In order to understand the role of EOMES in TR1 cells, we
turned to animal models and took advantage of Eomes-GFP
reporter mice (Eomes+/GFP) in which Eomes-expressing
CD4+ T cells can be identified as GFP-positive cells [37].
As we have previously demonstrated that adoptive transfer































































































































































Fig. 1 EOMES+ PD-1+ TR1-like cells with cytotoxic function
accumulate in CLL lymph node samples. A Paired PB and lymph
node (LN) samples of patients with CLL were analyzed by flow
cytometry. Representative dot plots as well as frequency of Eomes+
PD-1+ TR1-like cells. B LN samples of CLL patients were stimulated
with PMA/ionomycin ex vivo. nMFI of CD107a, and frequency of
IFNγ+ cells of PD-1+ or PD-1− CD4+ T cells. C Representative
contour plots and frequency of EOMES+ PD-1+ TR1-like cells out of
CD4+ T cells in reactive, nonpathogenic lymph nodes (rLN) and CLL
patient LN samples. Each dot represents data of an individual patient.
Data derived from paired samples are connected by a line. In (C),
median of data is depicted. Statistical analysis was performed using
Mann–Whitney test. Comparison of matched samples was performed
using Wilcoxon matched-pairs signed rank test *p < 0.05.
nMFI = normalized median fluorescence intensity.
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leads to an accumulation of EOMES+ PD-1+ cells with TR1
phenotype [28], we transferred CD4+ T cells of Eomes-GFP
reporter mice into Rag2−/− mice, and 3 weeks later, sorted
GFP-positive and GFP-negative CD4+ T cells of these mice
for RNA sequencing. This allowed us to identify a tran-
scriptional signature of 1,048 genes, with 568 upregulated
and 480 downregulated genes, in Eomes-GFP-positive
versus Eomes-GFP-negative CD4+ T cells (Fig. 2A, com-
parison 1, and Supplementary Tables 5 and 6). As expected,
one of the top upregulated genes was Eomes itself, vali-
dating our experimental approach. Among the top upregu-
lated genes in GFP+ cells, we identified several molecules
Eomes +/GFP Eomes ΔT/GFP
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Eomes +/GFP GFP pos
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that were associated with a TR1 phenotype in mice and men,
such as Il10, Il10ra, Pdcd1 (encoding PD-1), Lag3, Tigit,
and Cd27 (Supplementary Table 6) [5]. This supports the
validity of EOMES as a marker for TR1 cells. Among the
top downregulated genes in GFP+ cells, we detected Foxp3
(Supplementary Table 6), which is in line with our previous
findings of an antagonistic relationship between Eomes and
Foxp3 [28].
To analyze the relevance of EOMES in regulating TR1 cell
identity, we included a Eomes knock-out mouse model
(EomesΔT/GFP) in which one allele of the Eomes gene is
disrupted by a GFP knock-in, while the second allele lacks
exons 2–5, which encode the DNA-binding domain of
EOMES. The truncated mRNA and protein of this second
Eomes allele are expressed and detectable in these mice
(Supplementary Fig. 3A), but EOMES is dysfunctional and
cannot induce target genes [38]. Hence, GFP expression in
these mice identifies cells with active Eomes transcription,
but lack of EOMES activity. We used the same adoptive
transfer approach of CD4+ T cells in Rag2−/− hosts as
described above, and performed RNA sequencing of sorted
GFP+ and GFP− CD4+ T cells 3 weeks after the transfer.
This allowed us to compare gene expression profiles of
EOMES-proficient and EOMES-deficient CD4+ T cells upon
activation of Eomes transcription, and thereby to determine
which genes are transcriptionally regulated by EOMES
(Fig. 2A, comparison 2). The results of these comparative
analyses showed that 109 genes were dependent on tran-
scriptional activity of EOMES, with 71 genes showing a
lower expression in EOMES-deficient cells, which are
therefore most likely direct transcriptional targets of EOMES,
while 38 genes showed a higher expression in EOMES-
deficient cells (Fig. 2B and Supplementary Table 6).
Despite a low number of differentially expressed genes,
EOMES-deficient GFP+ cells from two biological replicates
clustered separately from EOMES-proficient GFP+ samples
on a multidimensional scaling plot (Supplementary Fig. 3B).
This suggests that EOMES transcriptional proficiency is
indeed required to express a specific transcriptional program.
As expected, the GFP-negative samples of both genotypes
did not separate well.
Out of these 109 genes, 61 genes were also differentially
expressed in comparison 1 representing the transcriptional
signature of TR1 cells (Supplementary Fig. 3C; genes
highlighted in bold in Fig. 2B), indicating that the TR1
phenotype is driven partly by EOMES.
EOMES has been previously associated with T-cell
exhaustion, and abundant expression of inhibitory receptors
is a hallmark of TR1 cells [5]. In line with this, we observed
that expression of several inhibitory receptor genes, such as
Ctla4, Pdcd1, Cd300lf, and Tigit, depends on EOMES, and so
does the expression of the exhaustion-associated transcription
factor Tox [39, 40] (genes highlighted in red in Fig. 2B; read
alignment for Pdcd1 and Lag3 in Fig. 2C). We further vali-
dated that EOMES+ cells show a higher protein expression of
PD-1 and LAG3 in comparison to EOMES− cells (Fig. 2C).
Using Ingenuity Pathway Analysis of the differentially
expressed genes in comparisons 1 and 2, we identified
“neuroinflammation signaling” and “T-cell exhaustion sig-
naling” as the top deregulated pathways in GFP+ cells that are
controlled by EOMES (Supplementary Fig. 3D). Altogether,
our results suggest that EOMES, via its relevance in TR1 cells,
contributes to pathogenesis of inflammatory diseases and
potentially also of cancer, including CLL.
To address the question whether EOMES only promotes
transcription of a few specific genes (e.g., inhibitory
receptors) or acts as a driver of TR1 cells, we developed a
marker combination for flow cytometry, which allowed us
to enrich for EOMES+ CD4+ T cells in the Rag2−/−
adoptive transfer model. We observed that EOMES+ cells
contain the majority of PD-1+ CD44lo cells in these mice
(Supplementary Fig. 3E). Interestingly, adoptive transfer of
Eomes-deficient naive CD4+ T cells yielded a significantly
lower number of PD-1+ CD44lo CD4+ T cells compared to
transfer of Eomes-proficient cells, an effect that was pre-
served when both Eomes-proficient and -deficient T cells
were co-transferred into the same Rag2−/− recipient (Sup-
plementary Fig. 3F). These results suggest that EOMES does
not only activate the expression of several target genes but is
rather controlling the accumulation of this specific CD4+ T-
cell subset. Whereas the marker combination PD-1+ CD44lo
was suitable to identify EOMES+ CD4+ T cells in T-cell
transfer experiments in Rag2−/− mice, a respective cell
population was not detectable in aged mice (Supplementary
Fig. 3E), which argues against the general suitability of this
marker combination for identifying TR1 cells.
Fig. 2 EOMES controls a TR1 cell-specific gene signature includ-
ing inhibitory receptors in CD4+ T cells. Naive CD25− CD45RBhigh
CD4+ T cells of Eomes-GFP reporter mice (Eomes+/GFP), and of mice
with a T cell-specific deletion of Eomes in combination with a GFP
reporter (EomesΔT/GFP) were transferred into Rag2−/− mice. Three
weeks after adoptive transfer, RNA sequencing of sorted splenic GFP+
and GFP− CD4+ T-cell subsets was performed. A Analysis strategy:
comparison 1 reveals transcriptional differences between GFP+
TR1 cells and GFP
− CD4+ T cells from Eomes+/GFP donor mice;
comparison 2 shows differential gene expression between EOMES-
proficient (Eomes+/GFP) and EOMES-deficient (EomesΔT/GFP) GFP+
CD4+ T cells. B Heatmap of log2 normalized expression of EOMES-
dependent genes (comparison 2). T-cell receptor transcripts were
excluded from the heatmap. Bold font shows genes which are also
differentially expressed in comparison 1. Red highlights genes of
interest. C Representative RNA-seq tracks and flow cytometry plots of
PD-1 and LAG3 expression in Eomes-GFP+ and Eomes-GFP− CD4+
T cells, and quantification of percentage PD-1- or LAG3-expressing
cells out of GFP+ or GFP− cells. Each dot represents data of an
individual mouse. Lines link data of EOMES− and EOMES+ cells
from the same animal. Statistical analysis of matched samples in (C)
was performed using Wilcoxon matched-pairs signed rank test.
***p < 0.001; ****p < 0.0001.
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In summary, our transcriptome analyses identify a TR1
cell-specific gene signature that includes several inhibitory
receptors and is enriched for key TR1-associated pathways
and markers. We further show that a part of this signature is
driven by EOMES.
EOMES drives IL-10 expression and genes enriched
in the human TR1 signature
To further investigate pathways controlled by EOMES in
TR1 cells, we performed KEGG pathway analysis. The top
identified pathway map was “cytokine–cytokine receptor
interaction,” followed by several pathways in which cyto-
kines are of major importance (Supplementary Fig. 4A).
This suggests that EOMES regulates cytokines and cytokine
receptors in TR1 cells. Along this line, we identified among
the upregulated genes in GFP+ cells that depend on the
presence of EOMES, the TR1 signature cytokine Il10
(Fig. 2B and Supplementary Fig. 4B), which is in agree-
ment with previous reports [2–4]. Transplantation of T cells
into Rag2−/− mice confirmed that the majority of IL-10-
producing CD4+ T cells co-express EOMES (Fig. 3A).
Importantly, most IL-10-producing cells also co-expressed
IFNγ (Fig. 3B), concordant with previously published TR1
descriptions [3, 41]. IL-10/IFNγ co-expression was depen-
dent on EOMES and not on non-cell autonomous factors
within the microenvironment, as Eomes-deficient CD4+
T cells did not produce IL-10, regardless whether they were
transferred alone or together with Eomes-proficient, CD4+
T cells (Fig. 3B).
Finally, we performed gene set enrichment analysis,
which showed that the identified EOMES-dependent tran-
scripts in GFP+ cells (comparison 2) were enriched in a
published human TR1 gene signature (Fig. 3C). Beyond
underlining the similarity between human and mouse
TR1 cells, these results confirm that a small subset of
EOMES-dependent genes is crucial for TR1 cell identity.
Leukemia development in the Eµ-TCL1 mouse
model is associated with an accumulation of
cytotoxic TR1 cells
To explore the role of TR1 cells (defined as EOMES
+ PD-1+)
in CLL, we first analyzed their presence in the Eµ-TCL1
(TCL1) mouse model of CLL. Comparing age- and sex-
matched leukemic TCL1 mice and WT littermates revealed a
higher abundance of TR1 cells in the spleen of TCL1 mice
(Fig. 4A, gating strategy in Supplementary Fig. 5A). The
majority of these EOMES+ PD-1+ cells also expressed LAG3
(Supplementary Fig. 5B), which we previously showed to be
dependent on EOMES. To overcome long latency of CLL
development in this mouse model, leukemic splenocytes of
TCL1 mice were adoptively transferred into syngeneic WT
mice (TCL1 AT), as previously described [34, 42, 43]. Upon
leukemia development in the TCL1 AT model, we observed
an accumulation of antigen-experienced CD4+ T cells (Sup-
plementary Fig. 5C) that show signs of activation as measured
by CD69 expression (Supplementary Fig. 5D). Moreover, a
higher frequency of TR1 CD4
+ T cells was detected (Fig. 4A),
which showed a high co-expression rate of LAG3 (Supple-
mentary Fig. 5B). Interestingly, the frequency of TR1 cells
was higher in aging Eµ-TCL1 mice compared to the younger
TCL1 AT mice (Fig. 4A), which is in line with our previous
observation that EOMES+ CD4+ T cells accumulate with age
[28].
Functional investigation of TR1 cells in TCL1 AT mice
confirmed the phenotype observed in CLL patients, with an
induced IL-10 expression that increased over time (Fig. 4B
and Supplementary Fig. 5E), and higher levels of IFNγ,
CD107a, and GzmB (Supplementary Fig. 5F, G), as mar-
kers of cytotoxicity, in these cells. These data show that
TR1 cells, which produce IL-10 and harbor cytotoxic
potential, accumulate in mouse models of CLL.
To investigate the impact of this cell type on CLL pro-
gression, we transferred CD4+ T cells into Rag2−/− mice,
which lack mature B and T cells [44] to exclude the con-
tribution of CD8+ T cells to leukemia control. Next, the
mice were transplanted with TCL1 leukemia cells, as pre-
viously described [34, 42, 43]. As reported before in other
mouse models, we detected an expansion of CD4+ T cells
in Rag2−/− mice with and without transfer of leukemic cells
(Supplementary Fig. 6A). Interestingly, CD4+ T cells con-
trolled leukemia progression, as indicated by lower spleen
weight and leukemia cell content per spleen compared to
mice without T-cell transfer (Supplementary Fig. 6B, C). Of
interest, CD4+ T cells from spleens of leukemia-bearing
Rag2−/− mice showed a higher frequency of TR1 cells
(Supplementary Fig. 6D) in comparison to non-leukemic
control mice, accompanied by a high co-expression of
LAG3 on these cells (Supplementary Fig. 6E). The leu-
kemic challenge of animals induced a higher proliferation
rate of TR1 cells in comparison to non-diseased mice
(Supplementary Fig. 6F). In contrast, the cytotoxic ability of
TR1 cells was not changed upon development of TCL1
leukemia (Supplementary Fig. 6G, H).
Next, we clustered FOXP3− CD4+ T cells derived of
mice with and without TCL1 AT based on their expression
of EOMES, PD-1, LAG3, and KI-67 measured by flow
cytometry using T-distributed Stochastic Neighbor
Embedding (t-SNE) algorithm to infer if CLL development
is changing the phenotype of this cell type. As expected
based on prior analyses, TR1 cells clustered similar,
regardless if mice were challenged with leukemic cells or
not (Supplementary Fig. 6I), suggesting that TCL1 leuke-
mia does not alter the phenotype of this cell type but rather
induces its expansion.
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In sum, the accumulation of cytotoxic TR1 cells advises
to investigate their role in controlling CLL progression.
EOMES is indispensable for TR1 cell-mediated
control of leukemia development in TCL1 AT mice
To analyze the role of TR1 cells in controlling CLL progres-
sion, we utilized conditional Eomes knock-out (Eomes−/−)
mice, as we have shown that EOMES is essential for the
generation of functional TR1 cells, in concordance with pre-
vious reports [2]. WT or Eomes−/− CD4+ T cells were
transplanted into Rag2−/− mice followed by adoptive transfer
of TCL1 leukemia cells. Analysis of CLL progression in these
mice showed that Eomes−/− CD4+ T cells failed to control
CLL development as evidenced by higher numbers of CD5+
CD19+ CLL cells in blood and higher spleen weights
(Fig. 5A). We further monitored CD4+ T-cell expansion in
these mice over time and observed higher T-cell numbers in
the blood of recipient mice of Eomes−/− CD4+ T cells com-
pared to WT T cells (Fig. 5B). However, in the spleen of these
animals, a lower absolute number of CD4+ T cells per spleen
and per CLL cell was noted in the Eomes−/− in comparison to
the WT group (Fig. 5C). In line with this, Eomes−/− T cells in
the spleen showed a lower proliferation rate based on KI-67
staining compared to WT T cells (Fig. 5D), suggesting that
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Fig. 3 EOMES-expressing CD4+ T cells express IL-10 and map
with TR1 cells. Cells for analyses were prepared as described in Fig. 2.
A Representative dot plot and quantification of IL-10 production by
splenic EOMES+ and EOMES− CD4+ T cells 3 weeks post transfer
into Rag2−/− hosts as analyzed by intracellular flow cytometry after
stimulation with PMA/ionomycin ex vivo. B Congenically labeled
EOMES-proficient (Control) or EOMES-deficient (KO) CD4+ T cells
were transferred into separate, or the same Rag2−/− hosts, and 3 weeks
later, splenocytes were analyzed by flow cytometry. Dot plots
show representative expression of IL-10 and IFNγ. Quantification of
IL-10-producing CD4+ T cells in single transfer and co-transfer
experiments is depicted at the bottom. C Gene set enrichment analysis
plot showing that EOMES-dependent TR1 genes (comparison 2 in
Fig. 2A) are enriched in human TR1 signature genes [3]. Each dot
represents data of an individual mouse. Lines in (A) link data of
EOMES− and EOMES+ cells from the same mouse; lines in (B) show
median. Statistical analysis was performed using Mann–Whitney test.
Comparison of matched samples in co-transfer setting was performed
using Wilcoxon matched-pairs signed rank test. *p < 0.05, **p < 0.01.
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data showed an enrichment and higher activation state of
TR1 cells in lymphoid organs of CLL patients, we subse-
quently analyzed splenic T cells of these mice for TR1-related
molecules. In line with the RNA-sequencing results, EOMES-
deficiency resulted in a reduced expression of LAG3 in
comparison to WT T cells (Fig. 5E). Moreover, EOMES was
indispensable for IL-10 production (Fig. 5F) and cytotoxic
function, as we observed a lower expression of IFNγ, a slight
reduction in CD107a, and a significantly lower production of
GzmB in EOMES-deficient T cells (Fig. 5G).
In summary, EOMES is important for the control of CLL
progression in mice as it mediates expansion and cyto-
toxicity of CD4+ T cells.
IL-10R signaling maintains cytotoxic TR1 cells and
allows them to control CLL
Ingenuity pathway analysis of Eomes-dependent genes
indicated Il10 and Stat3 as the top potential upstream reg-
ulators (Supplementary Table 7). In line, IL-10R signaling
has been shown to be essential for TR1 function [45].
Therefore, we decided to investigate the role of IL-10R-
mediated signaling in TR1 cells and its impact on control of
TCL1 leukemia. Either Il10rb+/+ (WT) or Il10rb−/− CD4+
T cells were injected into Rag2−/− mice followed by
transplantation of TCL1 leukemia. Of interest, Il10rb-defi-
cient CD4+ T cells showed a reduced control of CLL as
measured by higher CD5+ CD19+ CLL counts in blood
over time and by higher spleen weights 4 weeks after TCL1
AT in comparison to control mice receiving WT T cells
(Fig. 6A). To evaluate whether a reduced expansion of
Il10rb−/− CD4+ T cells contributes to the diminished CLL
control, T-cell counts were monitored in blood over time.
Three and 4 weeks after transfer of leukemic cells, a higher
number of Il10Rb−/− versus WT CD4+ T cells was seen in
blood (Fig. 6B). CD4+ T-cell counts in spleen showed a
trend toward a higher number of Il10rb−/− CD4+ T cells
compared to WT T cells per spleen (Supplementary
Fig. 7A), which is likely a reflection of the bigger spleen
sizes in the Il10rb−/− group, as the number of CD4+ T cells
per CLL cell was reduced in these mice in comparison
to the WT group (Fig. 6B). Nevertheless, proliferation of
CD4+ T cells, as measured by KI-67, did not differ sig-
nificantly between the two groups (Fig. 6C). Hence, IL-
10R-mediated signaling in CD4+ T cells is required for their
efficient control of CLL development which is not primarily
due to an impact on T-cell expansion.
IL-10Rα signaling was shown to be dispensable for the
differentiation of TR1 cells, but not for the function of this
cell type [45]. Similarly, we investigated the relevance of
Il10Rb for TR1 cells. As Il10rb
−/− CD4+ T cells showed a
higher frequency of TR1 cells than WT T cells (Fig. 6D), we
clustered FOXP3− CD4+ T cells of WT and Il10Rb−/−
origin based on their expression of EOMES, PD-1, LAG3,
and KI-67 measured by flow cytometry using t-SNE algo-





















































































































































young WT TCL1 ATB
Fig. 4 PD-1+ CD4+ T cells that co-express EOMES are enriched in
the Eµ-TCL1 mouse model of CLL. A Spleens of hemizygous Eµ-
TCL1 leukemic mice and control littermates at a median age of
65 weeks, or animals after transplantation of Eµ-TCL1 leukemic cells
into syngeneic wild type (WT) mice (TCL1 AT) were analyzed by
flow cytometry. Representative dot plots and frequency of TR1 cells
(EOMES+ PD-1+) out of CD4+ T cells in Eµ-TCL1 as well as TCL1
AT mice and their respective controls. B FIR × tiger mice were
transplanted with Eµ-TCL1 leukemic splenocytes and expression of
IL-10-GFP in splenic PD-1+ CD4+ T cells was analyzed by flow
cytometry. Representative dot plots as well as percentage of IL-10-
expressing cells out of CD4+ T cells in WT versus TCL1 AT FIR ×
tiger mice. All graphs show mean ± SEM. Each dot represents data of
an individual mouse. Statistical analysis was performed using
Mann–Whitney test. **p < 0.01; ***p < 0.001.
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PD-1+ CD4+ TR1-like cells of Il10Rb
−/− origin clustered
distinct of WT TR1 cells (Fig. 6E and Supplementary
Fig. 7B), likely driven by a higher expression of PD-1. This
suggests that IL-10R signaling is crucial for maintaining the
TR1 cell phenotype. This finding was further supported by a
reduced cytotoxic function of Il10rb−/− EOMES+ PD-1+
CD4+ T cells in comparison to WT TR1 cells (Fig. 6F),
arguing for a different phenotype of these cells arising upon
IL-10R deficiency.
Taken together, our data suggests that EOMES is indis-
pensable for the accumulation of cytotoxic TR1 cells, a cell
type whose function depends on IL-10R signaling and that
limits CLL progression.
Discussion
An altered frequency of CD4+ T-cell subsets in B-NHL
patients is widely described [9, 35, 42, 46], but their function
and pathological relevance are not well understood [1].
Therefore, we aimed to elucidate the role of PD-1-
expressing CD4+ T cells in these malignancies. By analyz-
ing blood samples of CLL and DLBCL patients, we
observed a higher proportion of PD-1-expressing CD4+
T cells in both patient groups compared to HC thus con-
firming published data [6–10]. Moreover, we noted that a
subset of PD-1+ cells co-expressed EOMES, which has
been observed for TR1 cells. Similar to PD-1-expressing
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Fig. 5 EOMES is crucial for TR1 cell-mediated CLL control.
Rag2−/− mice were transplanted i.v. with PBS or CD4+ T cells of wild
type (WT) or Eomes−/− origin on day -1 and the following day with
leukemic splenocytes of Eµ-TCL1 mice. Blood and spleen samples
were analyzed at indicated time points by flow cytometry. A Absolute
numbers of CD5+ CD19+ CLL cells in peripheral blood are shown
over time and spleen weights at endpoint, 4 weeks after transfer of
leukemic cells. B Absolute numbers of CD4+ T cells in peripheral
blood are depicted over time. C Numbers of CD4+ T cells per spleen,
and numbers of CD4+ T cells per CD5+ CD19+ CLL cell are shown.
D Percentages of KI-67+ cells out of splenic CD4+ T cells.
E Percentages of LAG3+ cells out of splenic PD-1+ CD4+ T cells.
F Expression of IL-10-GFP out of splenic PD-1+ CD4+ T cells shown
as representative histogram and quantification of data. G Splenocytes
were stimulated ex vivo with PMA/ionomycin and cytokine expres-
sion was analyzed by intracellular flow cytometry. Frequencies of
IFNγ+ cells out of PD-1+ CD4+ T cells, and nMFI of CD107a and
GzmB of PD-1+ CD4+ T cells. All graphs show mean ± SEM. Each
dot represents data of an individual mouse. Statistical analysis was
performed using Mann–Whitney test. *p < 0.05; **p < 0.01; ***p <
0.001. Tx = transplantation, nMFI = normalized median fluorescence
intensity.
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CD8+ T cells [34, 36], TR1-like T cells were enriched in LN
samples of CLL patients, the site of tight interactions
between malignant B and T cells and of their proliferation
[47, 48], and showed a higher activity than respective cells
in paired blood samples. We further observed that these cells
harbor cytotoxic capacities, which is in line with published
data shown for CD4+ T cells in the blood of B-NHL patients
[49–51]. Interestingly, these CD4+ T cells have been shown
to kill autologous B cells, regardless if they were derived
from CLL patients or HC [49].
TR1 cells do not constitutively express FOXP3, produce
the immunosuppressive cytokine IL-10, express co-inhibitory
receptors such as PD-1 or LAG3, and produce cytotoxic
molecules [5]. EOMES has recently been shown to be of
importance for the generation of TR1 cells [2, 3] and to reg-
ulate the expression of IL-10 in these cells [2, 3, 52]. Fur-
thermore, the importance of EOMES for the production of
cytotoxic molecules of CD4+ T cells is well described
[22, 23, 53]. Using RNA-sequencing and phenotypic analyses
of T cells from mouse models, we confirmed an overlap of
EOMES+ PD-1+ CD4+ T cells analyzed in our study with
human TR1 cells, and proved that EOMES is involved in their
generation and indispensable for their function. Of impor-
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Fig. 6 IL-10R signaling controls CLL development by maintaining
functional TR1 cells. Rag2
−/− mice were transplanted i.v. with PBS or
CD4+ T cells of wild type (WT) or Il10rb−/− origin on day -1 and the
following day with leukemic splenocytes of Eµ-TCL1 mice. Blood and
spleen samples were analyzed by flow cytometry. A Absolute numbers
of CD5+ CD19+ CLL cells in peripheral blood are shown over time
and spleen weights at endpoint, 4 weeks after transfer of leukemic
cells. B Absolute numbers of CD4+ T cells in peripheral blood are
depicted over time, and numbers of CD4+ T cells per CD5+ CD19+
CLL cell are shown. C Percentage of KI-67+ cells out of splenic CD4+
T cells. D Frequency of EOMES+ PD-1+ cells out of splenic CD4+
T cells. E t-SNE plots of concatenated, splenic WT TR1 cells and
Il10rb−/− EOMES+ PD-1+ CD4+ T cells based on flow cytometry
data for PD-1, EOMES, LAG3, and KI-67 expression (upper plots).
Overlay of both cell types in dark and light blue with WT FOXP3−
CD4+ T cells in gray (lower plot). F Splenocytes were stimulated
ex vivo with PMA/ionomycin and cytokine expression was analyzed
by intracellular flow cytometry. Frequencies of IFNγ+ cells out of PD-
1+ CD4+ T cells, and nMFI of CD107a and GzmB of PD-1+ CD4+
T cells. All graphs show mean ± SEM. Each dot represents data of an
individual mouse. Statistical analysis was performed using
Mann–Whitney. *p < 0.05; **p < 0.01; ***p < 0.001. nMFI = nor-
malized median fluorescence intensity.
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enriched in factors that were previously described for
TR1 cells, such as IL-10, PD-1, and LAG3. Among those
genes were also several integrins which might be involved in
migration and homing of T cells, and therefore responsible for
the higher number of EOMES-deficient compared to -profi-
cient CD4+ T cells remaining in the blood after their transfer
in Rag2−/− mice with CLL.
Intriguingly, using mouse models of CLL, we showed
that EOMES is essential for the CD4+ T cell-mediated
control of CLL in Rag2−/− mice. In these mice, CD4+
T cells expanded and acquired cytotoxic activity, which is in
line with similar results in mouse models of melanoma [54].
Since IL-10-driven signaling via p38 MAPK was shown
to be important to maintain IL-10 production in TR1 cells
[45], we investigated the role of IL-10R signaling in
TR1 cells and the control of leukemia progression. Interest-
ingly, Il10rb−/− CD4+ T cells showed a reduced CLL control
alongside with a high expression of PD-1 and EOMES, being
distinct from that of WT TR1 cells. This increase in PD-1 and
EOMES expression was accompanied by a reduction in IFNγ
production, suggesting that IL-10R signaling is important to
maintain a functional cytotoxic TR1 subset. This is in line
with published results for CD8+ T cells, showing that over-
expression of EOMES resulted in an increased expression of
exhaustion molecules such as CD244, Havcr2, and Il10ra,
implicating a role for IL-10-mediated signaling in regulating
T-cell exhaustion [55]. Studies in infection models and from
murine and human cancer showed that the expression level of
PD-1 in CD8+ T cells determines their state of exhaustion
and potential for reinvigoration by PD-1 blockade [56].
Along this line, we observed that IL-10-mediated signaling
maintains a subset of CD8+ T cells with intermediate PD-1
expression and high potential to control CLL in mice [57].
Together, this suggests that IL-10-mediated signals are
important to maintain effector function not only in CD8+
T cells but also in TR1 cells.
Genome-wide association studies showed that single
nucleotide polymorphisms (SNPs) in proximity of the
EOMES gene are associated with a higher risk of CLL
(rs9880772) [58, 59], DLBCL (rs6773363) [60], and
Hodgkin’s Lymphoma (rs3806624) [61]. The higher like-
lihood of B-NHL in individuals carrying these SNPs was
thought to be caused by a deregulated immune function,
which could at least partially be explained by the reduced
control of CLL development, as seen in our study. Along-
side, preclinical data in mouse models [62], and data of a
phase 1 basket trial (NCT02009449) using pegylated IL-10
for treatment of solid cancer, demonstrated that IL-10 helps
to maintain CD8+ T cell-mediated tumor control and
improves patients’ responses to PD-1 blockade [63].
In summary, this report highlights the presence of cyto-
toxic TR1 cells in LNs of CLL and DLBCL patients and in
the TCL1 mouse model of CLL. Our data in this animal
model clearly show that EOMES-expressing CD4+ T cells
are crucial for disease control. We further demonstrate the
importance IL-10-mediated signaling in maintaining
TR1 cells, which mediate effector activity and thus control
of leukemia.
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